RxDoctor Payments Data

Andrew Binder, MD

Internal Medicine · Santa Barbara, CANPI 1649367426

Payments from drug & device makers

$149,183in general payments, 2019–2025

Across 286 payments — averaging $521.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$127K
  • Takeda Pharmaceuticals U.S.A., Inc.$13K
  • Axsome Therapeutics, Inc.$8K
  • Harmony Biosciences LLC$600
  • Avadel CNS Pharmaceuticals, LLC$153
  • Advanced Respiratory, Inc$74
  • plus $166 from 6 others

What the payments were for

  • Consulting fees$24,97817%
  • Speaking & faculty fees$96,69065%
  • Travel & lodging$20,31314%
  • Food & beverage$6,8595%
  • Education$3430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$149,183 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$45,724
Medicare patients
136
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate24$485,553
XywavSodium,calcium,mag,pot Oxybate27$388,368
SunosiSolriamfetol Hcl11$9,418
Gabapentin96$1,016
Modafinil18$579
Pramipexole DihydrochloridePramipexole Di-Hcl18$410
Armodafinil14$337
Clonazepam45$308
Baclofen35$134
Methadone Hcl16$89
Lorazepam14$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Sunosi$8,270$9,41811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →